Advances in the Pharmacogenomics of Antiplatelet Therapy

Conclusions: Genotype-guided selection of antiplatelet therapy is expected to be useful in patients undergoing percutaneous coronary intervention (PCI) with a high risk of adverse outcomes. The patient–physician discussion should be an essential part of this decision-making process. Large-scale multicenter randomized controlled trials using the point-of-care genotype assay are needed to investigate this approach further before its use can be recommended in all comers.
Source: American Journal of Therapeutics - Category: Drugs & Pharmacology Tags: Therapeutic Advance Source Type: research